Titre : Oxidoreductases acting on sulfur group donors

Oxidoreductases acting on sulfur group donors : Questions médicales fréquentes

Termes MeSH sélectionnés :

Early Detection of Cancer
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Oxidoreductases acting on sulfur group donors : Questions médicales les plus fréquentes", "headline": "Oxidoreductases acting on sulfur group donors : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Oxidoreductases acting on sulfur group donors : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-16", "dateModified": "2025-04-10", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Oxidoreductases acting on sulfur group donors" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Oxidoreductases", "url": "https://questionsmedicales.fr/mesh/D010088", "about": { "@type": "MedicalCondition", "name": "Oxidoreductases", "code": { "@type": "MedicalCode", "code": "D010088", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.682" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Ferredoxine-NADP reductase", "alternateName": "Ferredoxin-NADP Reductase", "url": "https://questionsmedicales.fr/mesh/D005287", "about": { "@type": "MedicalCondition", "name": "Ferredoxine-NADP reductase", "code": { "@type": "MedicalCode", "code": "D005287", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.682.667.076" } } }, { "@type": "MedicalWebPage", "name": "Glutarédoxines", "alternateName": "Glutaredoxins", "url": "https://questionsmedicales.fr/mesh/D054477", "about": { "@type": "MedicalCondition", "name": "Glutarédoxines", "code": { "@type": "MedicalCode", "code": "D054477", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.682.667.084" } } }, { "@type": "MedicalWebPage", "name": "Glutathione reductase", "alternateName": "Glutathione Reductase", "url": "https://questionsmedicales.fr/mesh/D005980", "about": { "@type": "MedicalCondition", "name": "Glutathione reductase", "code": { "@type": "MedicalCode", "code": "D005980", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.682.667.092" } } }, { "@type": "MedicalWebPage", "name": "Hydrogensulfite reductase", "alternateName": "Hydrogensulfite Reductase", "url": "https://questionsmedicales.fr/mesh/D050885", "about": { "@type": "MedicalCondition", "name": "Hydrogensulfite reductase", "code": { "@type": "MedicalCode", "code": "D050885", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.682.667.124" } } }, { "@type": "MedicalWebPage", "name": "Protein-disulfide reductase (glutathione)", "alternateName": "Protein Disulfide Reductase (Glutathione)", "url": "https://questionsmedicales.fr/mesh/D011490", "about": { "@type": "MedicalCondition", "name": "Protein-disulfide reductase (glutathione)", "code": { "@type": "MedicalCode", "code": "D011490", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.682.667.186" } } }, { "@type": "MedicalWebPage", "name": "Sulfite dehydrogenase", "alternateName": "Sulfite Dehydrogenase", "url": "https://questionsmedicales.fr/mesh/D050902", "about": { "@type": "MedicalCondition", "name": "Sulfite dehydrogenase", "code": { "@type": "MedicalCode", "code": "D050902", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.682.667.217" } } }, { "@type": "MedicalWebPage", "name": "Sulfite oxidase", "alternateName": "Sulfite Oxidase", "url": "https://questionsmedicales.fr/mesh/D050876", "about": { "@type": "MedicalCondition", "name": "Sulfite oxidase", "code": { "@type": "MedicalCode", "code": "D050876", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.682.667.249" } } }, { "@type": "MedicalWebPage", "name": "Sulfite reductase (ferredoxin)", "alternateName": "Sulfite Reductase (Ferredoxin)", "url": "https://questionsmedicales.fr/mesh/D050889", "about": { "@type": "MedicalCondition", "name": "Sulfite reductase (ferredoxin)", "code": { "@type": "MedicalCode", "code": "D050889", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.682.667.374" } } }, { "@type": "MedicalWebPage", "name": "Sulfite reductase (NADPH)", "alternateName": "Sulfite Reductase (NADPH)", "url": "https://questionsmedicales.fr/mesh/D050864", "about": { "@type": "MedicalCondition", "name": "Sulfite reductase (NADPH)", "code": { "@type": "MedicalCode", "code": "D050864", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.682.667.500" } } }, { "@type": "MedicalWebPage", "name": "Thioredoxin reductase 1", "alternateName": "Thioredoxin Reductase 1", "url": "https://questionsmedicales.fr/mesh/D054481", "about": { "@type": "MedicalCondition", "name": "Thioredoxin reductase 1", "code": { "@type": "MedicalCode", "code": "D054481", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.682.667.750.500" } } }, { "@type": "MedicalWebPage", "name": "Thioredoxin reductase 2", "alternateName": "Thioredoxin Reductase 2", "url": "https://questionsmedicales.fr/mesh/D054482", "about": { "@type": "MedicalCondition", "name": "Thioredoxin reductase 2", "code": { "@type": "MedicalCode", "code": "D054482", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.682.667.750.750" } } } ], "about": { "@type": "MedicalCondition", "name": "Oxidoreductases acting on sulfur group donors", "alternateName": "Oxidoreductases Acting on Sulfur Group Donors", "code": { "@type": "MedicalCode", "code": "D050862", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Inês A C Pereira", "url": "https://questionsmedicales.fr/author/In%C3%AAs%20A%20C%20Pereira", "affiliation": { "@type": "Organization", "name": "Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal." } }, { "@type": "Person", "name": "Shi Xu", "url": "https://questionsmedicales.fr/author/Shi%20Xu", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, Washington State University, Pullman, WA, 99164, USA." } }, { "@type": "Person", "name": "Ming Xian", "url": "https://questionsmedicales.fr/author/Ming%20Xian", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, Washington State University, Pullman, WA, 99164, USA." } }, { "@type": "Person", "name": "Wei Li", "url": "https://questionsmedicales.fr/author/Wei%20Li", "affiliation": { "@type": "Organization", "name": "School of Environmental Science and Engineering, Suzhou University of Science and Technology, Suzhou 215009, China; National and Local Joint Engineering Laboratory for Municipal Sewage Resource Utilization Technology, Suzhou University of Science and Technology, Suzhou 215009, China." } }, { "@type": "Person", "name": "Dorry L Segev", "url": "https://questionsmedicales.fr/author/Dorry%20L%20Segev", "affiliation": { "@type": "Organization", "name": "Department of Surgery, New York University Grossman School of Medicine, New York, NY." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "DNA Methylation in the Fields of Prenatal Diagnosis and Early Detection of Cancers.", "datePublished": "2023-07-20", "url": "https://questionsmedicales.fr/article/37511475", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/ijms241411715" } }, { "@type": "ScholarlyArticle", "name": "A Liquid Biopsy Signature for the Early Detection of Gastric Cancer in Patients.", "datePublished": "2023-03-07", "url": "https://questionsmedicales.fr/article/36894035", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1053/j.gastro.2023.02.044" } }, { "@type": "ScholarlyArticle", "name": "Early detection of cancer therapy cardiotoxicity by radionuclide angiography: An update.", "datePublished": "2023-02-28", "url": "https://questionsmedicales.fr/article/36855007", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s12350-023-03202-w" } }, { "@type": "ScholarlyArticle", "name": "Optimal age to stop prostate cancer screening and early detection.", "datePublished": "2023-08-19", "url": "https://questionsmedicales.fr/article/37598870", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jcpo.2023.100443" } }, { "@type": "ScholarlyArticle", "name": "Serum IgG N-glycans enable early detection and early relapse prediction of colorectal cancer.", "datePublished": "2022-10-03", "url": "https://questionsmedicales.fr/article/36121650", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/ijc.34298" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Enzymes et coenzymes", "item": "https://questionsmedicales.fr/mesh/D045762" }, { "@type": "ListItem", "position": 3, "name": "Enzymes", "item": "https://questionsmedicales.fr/mesh/D004798" }, { "@type": "ListItem", "position": 4, "name": "Oxidoreductases", "item": "https://questionsmedicales.fr/mesh/D010088" }, { "@type": "ListItem", "position": 5, "name": "Oxidoreductases acting on sulfur group donors", "item": "https://questionsmedicales.fr/mesh/D050862" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Oxidoreductases acting on sulfur group donors - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Oxidoreductases acting on sulfur group donors", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-08", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Oxidoreductases acting on sulfur group donors", "description": "Comment diagnostiquer une déficience en oxydoréductases ?\nQuels tests sont utilisés pour évaluer l'activité des oxydoréductases ?\nLes tests génétiques sont-ils utiles pour le diagnostic ?\nQuels symptômes peuvent indiquer un problème enzymatique ?\nComment les analyses sanguines aident-elles au diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D050862?mesh_terms=Early+Detection+of+Cancer&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Oxidoreductases acting on sulfur group donors", "description": "Quels sont les symptômes d'une déficience en sulfure d'hydrogène ?\nComment se manifestent les troubles métaboliques liés aux oxydoréductases ?\nLes symptômes varient-ils selon le type d'oxydoréductase ?\nQuels signes cliniques sont associés aux maladies métaboliques ?\nLes troubles respiratoires peuvent-ils être liés aux oxydoréductases ?", "url": "https://questionsmedicales.fr/mesh/D050862?mesh_terms=Early+Detection+of+Cancer&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Oxidoreductases acting on sulfur group donors", "description": "Comment prévenir les maladies liées aux oxydoréductases ?\nLes dépistages précoces sont-ils recommandés ?\nL'éducation des patients est-elle importante ?\nLes vaccinations peuvent-elles jouer un rôle préventif ?\nComment le mode de vie influence-t-il la prévention ?", "url": "https://questionsmedicales.fr/mesh/D050862?mesh_terms=Early+Detection+of+Cancer&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Oxidoreductases acting on sulfur group donors", "description": "Quels traitements sont disponibles pour les déficiences enzymatiques ?\nLa thérapie génique est-elle une option pour ces maladies ?\nComment les médicaments peuvent-ils aider ?\nLes traitements sont-ils personnalisés selon le patient ?\nQuels rôles jouent les diététiciens dans le traitement ?", "url": "https://questionsmedicales.fr/mesh/D050862?mesh_terms=Early+Detection+of+Cancer&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Oxidoreductases acting on sulfur group donors", "description": "Quelles complications peuvent survenir avec ces déficiences ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles la qualité de vie ?\nLes complications peuvent-elles être prévenues ?\nQuels sont les risques de complications à long terme ?", "url": "https://questionsmedicales.fr/mesh/D050862?mesh_terms=Early+Detection+of+Cancer&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Oxidoreductases acting on sulfur group donors", "description": "Quels sont les facteurs de risque pour les maladies métaboliques ?\nL'âge est-il un facteur de risque ?\nLe stress peut-il influencer ces maladies ?\nLes habitudes alimentaires jouent-elles un rôle ?\nLes facteurs environnementaux sont-ils significatifs ?", "url": "https://questionsmedicales.fr/mesh/D050862?mesh_terms=Early+Detection+of+Cancer&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une déficience en oxydoréductases ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests enzymatiques et des analyses biochimiques sont utilisés pour diagnostiquer." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'activité des oxydoréductases ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de spectrophotométrie et des dosages enzymatiques sont couramment utilisés." } }, { "@type": "Question", "name": "Les tests génétiques sont-ils utiles pour le diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tests génétiques peuvent identifier des mutations affectant les oxydoréductases." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un problème enzymatique ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme la fatigue, des douleurs musculaires ou des troubles métaboliques peuvent survenir." } }, { "@type": "Question", "name": "Comment les analyses sanguines aident-elles au diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les analyses sanguines mesurent les niveaux de métabolites et d'enzymes spécifiques." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une déficience en sulfure d'hydrogène ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des troubles neurologiques, des douleurs abdominales et des nausées." } }, { "@type": "Question", "name": "Comment se manifestent les troubles métaboliques liés aux oxydoréductases ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent se manifester par des déséquilibres électrolytiques et des anomalies de croissance." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon le type d'oxydoréductase ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier en fonction de l'enzyme spécifique impliquée." } }, { "@type": "Question", "name": "Quels signes cliniques sont associés aux maladies métaboliques ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme l'hyperlipidémie, l'hyperglycémie et des anomalies hépatiques peuvent apparaître." } }, { "@type": "Question", "name": "Les troubles respiratoires peuvent-ils être liés aux oxydoréductases ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains troubles respiratoires peuvent être causés par des déséquilibres métaboliques." } }, { "@type": "Question", "name": "Comment prévenir les maladies liées aux oxydoréductases ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et des bilans de santé réguliers peuvent aider à prévenir ces maladies." } }, { "@type": "Question", "name": "Les dépistages précoces sont-ils recommandés ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des dépistages précoces peuvent identifier des anomalies enzymatiques avant l'apparition des symptômes." } }, { "@type": "Question", "name": "L'éducation des patients est-elle importante ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, informer les patients sur les signes et symptômes peut aider à une détection rapide." } }, { "@type": "Question", "name": "Les vaccinations peuvent-elles jouer un rôle préventif ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Certaines vaccinations peuvent prévenir des infections qui aggravent les troubles métaboliques." } }, { "@type": "Question", "name": "Comment le mode de vie influence-t-il la prévention ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain, incluant exercice et nutrition, peut réduire le risque de maladies métaboliques." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour les déficiences enzymatiques ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des suppléments enzymatiques et des modifications diététiques." } }, { "@type": "Question", "name": "La thérapie génique est-elle une option pour ces maladies ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la thérapie génique est explorée comme une option pour corriger des déficiences spécifiques." } }, { "@type": "Question", "name": "Comment les médicaments peuvent-ils aider ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Certains médicaments peuvent aider à réguler les niveaux de métabolites et à soulager les symptômes." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés selon le patient ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements sont souvent adaptés en fonction des besoins individuels du patient." } }, { "@type": "Question", "name": "Quels rôles jouent les diététiciens dans le traitement ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les diététiciens aident à concevoir des régimes alimentaires adaptés aux besoins métaboliques." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec ces déficiences ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme des troubles neurologiques, des maladies cardiovasculaires peuvent survenir." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être réversibles avec un traitement approprié, d'autres non." } }, { "@type": "Question", "name": "Comment les complications affectent-elles la qualité de vie ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent réduire la qualité de vie en limitant les activités quotidiennes et en causant de la douleur." } }, { "@type": "Question", "name": "Les complications peuvent-elles être prévenues ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une gestion proactive des symptômes et un suivi médical régulier peuvent aider." } }, { "@type": "Question", "name": "Quels sont les risques de complications à long terme ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les risques incluent des maladies chroniques et des défaillances organiques si non traitées." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les maladies métaboliques ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux, une mauvaise alimentation et le manque d'exercice." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'âge avancé peut augmenter le risque de développer des troubles métaboliques." } }, { "@type": "Question", "name": "Le stress peut-il influencer ces maladies ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut aggraver les symptômes et augmenter le risque de complications." } }, { "@type": "Question", "name": "Les habitudes alimentaires jouent-elles un rôle ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en graisses et en sucres peut augmenter le risque de maladies." } }, { "@type": "Question", "name": "Les facteurs environnementaux sont-ils significatifs ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des toxines environnementales peut affecter l'activité des oxydoréductases." } } ] } ] }

Sources (10000 au total)

A Liquid Biopsy Signature for the Early Detection of Gastric Cancer in Patients.

Diagnosing gastric cancer (GC) while the disease remains eligible for surgical resection is challenging. In view of this clinical challenge, novel and robust biomarkers for early detection thus improv... The present 3-step study incorporated data from 2141 patients, including 888 with GC, 158 with chronic atrophic gastritis, 193 with intestinal metaplasia, 501 healthy donors, and 401 with other gastro... In discovery phase, one LR (GClnc1) was found to be up-regulated in both tissue and circulating EV samples with an area under the curve (AUC) of 0.9369 (95% confidence interval [CI], 0.9073-0.9664) fo... EV-derived GClnc1 serves as a circulating biomarker for the early detection of GC, thus providing opportunities for curative surgery and improved survival outcomes....

Optimal age to stop prostate cancer screening and early detection.

Prostate Cancer screening should be discontinued at older ages because competing mortality risks eventually dominate the risk of Prostate Cancer and harms exceed benefits. We explored the Prostate Can... We applied Bellman Equations to formulate the net benefits biopsy and "do nothing". Using difference between the net benefits of two alternatives, we calculated the stopping age. The cancer states wer... Our results suggested that Prostate Cancer screening stopping ages from the patient, healthcare system, and social were 70, 68, and 68 respectively. The univariate sensitivity analysis showed that the... Men should not be screened for Prostate Cancer beyond 70 years old, as this results in the net benefit of "do nothing" above the biopsy. Nevertheless, this finding needs to be further studied with mor...

Ovarian Cancer-Self Assessment: An Innovation for Early Detection and Risk Assessment of Ovarian Cancer.

The modality to detect ovarian cancer at an early stage is very limited. Early diagnosis determines the prognosis. This study aimed to develop a risk assessment tool for early detection of ovarian can... This study was carried out as a cohort study of patients diagnosed with suspected ovarian tumors undergoing cytoreduction operation at Hasan Sadikin Hospital, Bandung, from December 2019 to September ... In total, 115 patients included in this study. The differences were statistically significant in terms of the six variables (abdominal bloating, nausea/vomiting, decreased of appetite, fullness, menst... Risk assessments based on ovarian cancer self-assessment unfortunately were not comparable to postoperative histopathology as a single predictor. Ten variables in ovarian cancer artificial intelligenc...

Integration of multiomics features for blood-based early detection of colorectal cancer.

Early detection of colorectal cancer (CRC) significantly enhances patient outcomes. Conventional CRC screening tools, like endoscopy and stool-based tests, have constraints due to their invasiveness o... In this research, we harnessed the Mutation Capsule Plus (MCP) technology to profile an array of genomic characteristics from cfDNA procured from a single blood draw. This profiling encompassed DNA me... This model was subsequently validated in another cohort comprising 89 CRC patients and 95 healthy controls. Remarkably, the model achieved an area under the curve (AUC) of 0.981 (95% confidence interv... Our findings underscore the clinical potential of our multiomics liquid biopsy test, indicating its prospective role as a noninvasive method for early-stage CRC detection. This multiomics approach hol...

Prospective cohort for early detection of liver cancer (Pearl): a study protocol.

Hepatocellular carcinoma (HCC) is the fastest-rising and fourth most common cause of cancer death worldwide. Liver cirrhosis is the largest underlying risk factor for HCC. Therefore, patients with cir... This is a UK-based prospective, longitudinal, diagnostic, prognostic, multicentre, non-CTIMP study. Aiming to recruit 3000 patients with liver cirrhosis without a HCC diagnosis, the Pearl cohort will ... Ethical approval has been granted by REC and the trial is registered on ClinicalTrials.gov. The results will be published in peer-reviewed journals and presented at relevant meetings.... NCT05541601....